Phase I Dose Escalation Study of HFB200603, a Best-in-Class BTLA Antagonist Monoclonal Antibody in Monotherapy and in Combination with the Anti-PD-1 mAb Tislelizumab in Adult Patients with Advanced Solid Tumors

Phase I Dose Escalation Study of HFB200603, a Best-in-Class BTLA Antagonist Monoclonal Antibody in Monotherapy and in Combination with the Anti-PD-1 mAb Tislelizumab in Adult Patients with Advanced Solid Tumors